At 4.5% CAGR, Middle East & Africa Transient Protein Expression Market is Projected to be Worth US$ 56.92 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa transient protein expression market was valued at US$ 40.00 million in 2023 and is expected to reach US$ 56.92 million by 2031, registering a CAGR of 4.5% from 2023 to 2031. Plant-based expression systems for therapeutic protein production and integration of artificial intelligence (AI) & automation technologies are among the critical factors attributed to drive the Middle East & Africa transient protein expression market growth.

The use of microbial or mammalian cell-based expression systems has been a common practice in recombinant protein production processes; however, plant-based expression has been promoted as a cost-effective, scalable, safe, and sustainable alternative in recent years. The duration of protein synthesis has been greatly shortened and the yield of recombinant proteins in plants has improved thanks to the creation and advancement of transient expression methods. A shift in consumer preference toward plant-based products compels pharmaceutical and biopharmaceutical companies to focus on plant-based synthesis of therapeutic proteins. The use of plants has excellent potential for improving yields of proteins that can be administered for the prevention or treatment of human and animal diseases. The use of therapeutic proteins is likely to surge in the healthcare sector in the coming years due to the ongoing restructuring of regulatory frameworks and growing awareness about transient protein expression in plants. Maximum Scale‐up possibility, low growth costs, complex protein production ability, low contamination (especially involving human pathogens) risks, and optimized growth conditions are among the key advantages associated with transient protein expression in plants. Moreover, plants are considered safer compared to other expression systems as they do not produce endotoxins and cause less harm to humans. Thus, plant-based expression systems for therapeutic protein expression are emerging as vital opportunities for the transient protein expression market growth during the forecast period.

On the contrary, high cost of products hampers the growth of Middle East & Africa transient protein expression market.

Based on product type, the Middle East & Africa transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held 35.4% market share in 2023, amassing US$ 14.17 million. It is projected to garner US$ 20.49 million by 2031 to register 4.7% CAGR during 2023–2031.

In terms of application, the Middle East & Africa transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held 32.9% share of Middle East & Africa transient protein expression market in 2023, amassing US$ 13.15 million. It is anticipated to garner US$ 19.99 million by 2031 to expand at 5.4% CAGR during 2023–2031.

Based on end user, the Middle East & Africa transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held 54.9% share of Middle East & Africa transient protein expression market in 2023, amassing US$ 21.97 million. It is anticipated to garner US$ 32.17 million by 2031 to expand at 4.9% CAGR during 2023–2031.

By country, the Middle East & Africa transient protein expression market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 40.1% share of Middle East & Africa transient protein expression market in 2023. It was assessed at US$ 16.04 million in 2023 and is likely to hit US$ 22.49 million by 2031, registering a CAGR of 4.3% during 2023–2031.

Key players operating in the Middle East & Africa transient protein expression market are Thermo Fisher Scientific Inc, Merck KGaA, QIAGEN NV, GenScript Biotech Corporation, Promega Corp, Takara Bio Inc, New England Biolabs, Agilent Technologies Inc, Mirus Bio LLC, Bio-Rad Laboratories Inc, Lonza Group AG, and MaxCyte Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com